Mitchell Brigell,Peter End,Vinayak Hosagrahara,Bruce D. Jaffee,Erik Meredith,Ronald Keith Newton,Stephen Poor,Yubin Qiu
申请号：
US13878678
公开号：
US20130197016A1
申请日:
2011.10.25
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The use of vascular endothelial growth factor receptor 2 inhibitors or a pharmaceutically acceptable salt thereof for the treatment of ocular vascular disease is provided. Dosing regimes, including once weekly administration, of certain VEGF-R2 inhibitors are provided which deliver therapeutically effective concentrations of the VEGF-R2 compounds in ocular tissues for at least one week for the treatment of ocular vascular disease.
